All Updates

All Updates

icon
Filter
Partnerships
Foundation Medicine and PMV Pharmaceuticals partner to develop companion diagnostic for rezatapopt
Precision Medicine
May 29, 2024
This week:
Funding
GrayMatter Robotics raises USD 45 million in Series B funding to accelerate AI-powered robotics solutions
Smart Factory
Yesterday
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Logistics Tech
Yesterday
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Smart Factory
Yesterday
Funding
FairNow raises USD 3.5 million to advance AI governance solutions
Generative AI Infrastructure
Yesterday
Partnerships
Gravitics develops testing gauntlet for larger spacecraft in collaboration with NASA
Space Travel and Exploration Tech
Yesterday
M&A
knownwell acquires Alfie Health to integrate AI in primary and obesity care services
Telehealth
Yesterday
Funding
Pomelo Care raises USD 46 million in Series B funding to expand virtual maternal care
Telehealth
Yesterday
Funding
Isar Aerospace raises EUR 65 million, backed by NATO Innovation Fund
Space Travel and Exploration Tech
Yesterday
Product updates
Beyond Meat releases new Beyond Sausage, expanding its Beyond IV product line
Plant-based Meat
Yesterday
Product updates
Funding
SurrealDB raises USD 20 million in Series A; launches beta version of Surreal Cloud
Data Infrastructure & Analytics
Yesterday
Precision Medicine

Precision Medicine

May 29, 2024

Foundation Medicine and PMV Pharmaceuticals partner to develop companion diagnostic for rezatapopt

Partnerships

  • Foundation Medicine has partnered with PMV Pharmaceuticals to develop FoundationOneCDx, a tissue-based genomic profiling test, as a companion diagnostic for PMV Pharma's rezatapopt (PC14586).

  • Rezatapopt is an investigational, first-in-class therapy for patients with locally advanced or metastatic solid tumors with a TP53 Y220C mutation. It is designed to stabilize p53 Y220C proteins. It is the subject of the ongoing registrational, tumor-agnostic PYNNACLE Phase II clinical trial, and has been granted the Fast Track designation by the FDA for treating patients with locally advanced or metastatic solid tumors.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.